



## For testing performed in Ontario only

August 27, 2018

At Dynacare, our vision is to be Canada’s health and wellness solutions leader. As part of our continuous efforts to enhance our testing platforms and support customer care, Dynacare is implementing a new state-of-the-art chemistry platform in its Ontario laboratories in September. This platform will increase our testing capabilities and allow us to manage increases in healthcare demands over the years to come.

As part of the transition to the new platform, Dynacare has reviewed the current reference intervals and will be making the following changes.

### Effective August 27<sup>th</sup>, 2018, Dynacare will change the following reference intervals:

Test Name	Sex	Age (years)	Current Reference Interval		New Reference Interval		Units
			Low	High	Low	High	
Anti-Mullerian Hormone	M	≥ 20	1.43	17.00	0.77	14.5	ng/mL
	F	20 – 24	1.66	9.49	1.22	11.7	
		25 – 29	1.18	10.10	0.89	9.85	
		30 – 34	0.67	7.55	0.58	8.13	
		35 – 39	0.78	5.24	0.15	7.49	
		40 – 44	0.10	2.96	0.03	5.47	
		45 – 50	0.05	2.06	0.01	2.71	
		≥ 51	Reference Interval not established				
Polycystic Ovary Syndrome	2.41	17.1	1.86	18.9			
Bilirubin, Direct	M/F		<	5	<	8	µmol/L
FSH	M	≥ 13	2	12	1	16	IU/L
	F	≥ 13 (Follicular)	4	13	3	15	
		≥ 13 (Ovulatory)	5	22	5	23	
		≥ 13 (Luteal)	2	8	1	9	
		≥ 13 (Post-menopausal)	26	135	16	157	

Test Name	Sex	Age (years)	Current Reference Interval		New Reference Interval		Units
Insulin (Fasting)	M/F		40	190	15	174	pmol/L
LH	M	≥ 13	1.7	8.6	1.3	9.6	IU/L
	F	≥ 13 (Follicular)	2.4	12.6	1.9	14.6	
		≥ 13 (Ovulatory)	14.0	95.6	12.2	118	
		≥ 13 (Luteal)	1.0	11.4	0.7	12.9	
		≥ 13 (Post-menopausal)	7.7	58.5	5.3	65.4	
SHBG	M	≥ 50	14	80	19	83	nmol/L
	F	20 - 49	25	122	27	146	
		≥ 50	17	125	22	142	
Urate	M	12 - 17	200	440	202	464	μmol/L
	M	≥ 18	200	440	220	512	
	F	12 - 17	140	340	143	375	
	F	≥ 18	140	340	149	422	

**Effective September 10<sup>th</sup>, 2018, Dynacare will change the following reference intervals:**

Test Name	Sex	Age (years)					Units
			Low	High	Low	High	
Estradiol	F	≥ 13 (Follicular)	60	854	45	854	pmol/L

With the implementation of the new platform, there will be an improvement in analytical specificity for the HDL cholesterol test, with an expected decrease in HDL cholesterol results of about 8%. As HDL cholesterol is used in the calculation of LDL cholesterol, an increase in LDL cholesterol results is also expected. There will also be a change to the calibration traceability of the ALP test, with an expected increase in ALP results of about 10%. Reference intervals will not be changing for these two tests.

Dynacare is committed to providing the highest quality and value to our partners and to the overall healthcare system. For further information regarding the new reference intervals, please refer to [Dynacare.ca](http://Dynacare.ca), under News and Media/Partner Updates. If you would like to further discuss, please feel free to contact Customer Care at 800.565.5721 x 5752.

We appreciate your support and look forward to working with you as we strive to improve the quality of our services for all of our partners.

Peter Catomeris, PhD, FCACB  
 Scientific Director, Chemistry and Immunoassay